Market revenue in 2023 | USD 239.5 million |
Market revenue in 2030 | USD 242.5 million |
Growth rate | 0.2% (CAGR from 2023 to 2030) |
Largest segment | Immunoturbidimetric assay |
Fastest growing segment | Immunoturbidimetric Assay |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoturbidimetric Assay, Chemiluminescence Immunoassay, Other Assay Types, ELISA |
Key market players worldwide | Thermo Fisher Scientific Inc, Roche Holding AG ADR, Danaher Corp, Quest Diagnostics Inc, Siemens Healthineers AG ADR, Abbott Laboratories, Merck KGaA, Zoetis Inc Class A, QuidelOrtho Corp, Horiba Ltd, Getein Biotech, Boditech Med, Randox, Aidian |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to c-reactive protein testing market will help companies and investors design strategic landscapes.
Immunoturbidimetric assay was the largest segment with a revenue share of 48.48% in 2023. Horizon Databook has segmented the Canada c-reactive protein testing market based on immunoturbidimetric assay, chemiluminescence immunoassay, other assay types, elisa covering the revenue growth of each sub-segment from 2018 to 2030.
Canada CRP testing market is expected to grow at a CAGR higher than the U.S. Factors such as increase in investigational studies, supportive government initiatives, and rising incidence of chronic diseases such as cardiac & inflammatory disorders in the region are expected to drive the market in the near future.
A number of research studies in the region, conducted by several research laboratories, universities including McGill University, and other institutes, are also expected to boost market growth. According to Canadian Cancer Society, approximately half of the Canadian population is expected to be diagnosed with cancer in their lifetime.
As per Canadian Cancer Statistics, the number of cancer patients increased due to rise in geriatric population. However, it was observed that survival rate has increased over the past few years due to cancer prevention programs, early detection methods, and better treatment options.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada c-reactive protein testing market , including forecasts for subscribers. This country databook contains high-level insights into Canada c-reactive protein testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account